|
TOB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.99939997470278E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.99040000224005E-08 |
| Normal-vs-Stage2 |
5.70449999459655E-08 |
| Normal-vs-Stage3 |
5.57319967953163E-10 |
| Normal-vs-Stage4 |
4.78320000274479E-08 |
| Stage1-vs-Stage2 |
2.996400E-01 |
| Stage1-vs-Stage3 |
8.384000E-03 |
| Stage1-vs-Stage4 |
2.445000E-01 |
| Stage2-vs-Stage3 |
4.568200E-01 |
| Stage2-vs-Stage4 |
9.298000E-01 |
| Stage3-vs-Stage4 |
5.266600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.30809999498993E-08 |
| Normal-vs-AfricanAmerican |
7.884000E-03 |
| Normal-vs-Asian |
1.23249999983699E-07 |
| Caucasian-vs-AfricanAmerican |
2.025200E-01 |
| Caucasian-vs-Asian |
7.020400E-01 |
| AfricanAmerican-vs-Asian |
1.377180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.52889994792838E-09 |
| Normal-vs-Female |
1.64660000079309E-08 |
| Male-vs-Female |
4.785400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.76450000002981E-07 |
| Normal-vs-Age(41-60Yrs) |
6.12039996461533E-09 |
| Normal-vs-Age(61-80Yrs) |
2.08470019025242E-10 |
| Normal-vs-Age(81-100Yrs) |
2.769700E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.523700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.619300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.692000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.856300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.549400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.666430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.204750E-03 |
| Classical-VS-Follicular |
2.303800E-01 |
| Classical-VS-Other |
8.593400E-01 |
| Classical-VS-Normal |
1.35680000012961E-07 |
| Tall-VS-Follicular |
1.038020E-01 |
| Tall-VS-Other |
4.405200E-01 |
| Tall-VS-Normal |
2.83229995012846E-10 |
| Follicular-VS-Other |
8.391800E-01 |
| Follicular-VS-Normal |
4.33129999644066E-08 |
| Other-VS-Normal |
2.278200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.19830004094734E-09 |
| Normal-vs-N1 |
6.73240000415021E-08 |
| N0-vs-N1 |
9.565600E-01 |
|
|
